Description
Indication & Scope
PAXLOVID® Nirmatrelvir Tablets and Ritonavir Tablets (co-packaged) treats mild to moderate COVID-19 infection in adults with high risk of progression to severe disease within 5 days of symptom onset.
- Mechanism: Nirmatrelvir inhibits SARS-CoV-2 main protease to block viral maturation; ritonavir inhibits liver enzymes to slow nirmatrelvir metabolism and raise its blood concentration.
- Drug class: Combined protease inhibitor anti-SARS-CoV-2 antiviral agent.
- Clinical use: Early antiviral intervention to reduce hospitalization and mortality risks for high-risk mild-moderate COVID-19 cases.
| Generic Name | Nirmatrelvir Tablets and Ritonavir Tablets (co-packaged) |
| Brand Name | PAXLOVID |
| Ingredient | Nirmatrelvir and Ritonavir |
| Dosage Form | Tablets |
| Package | [Nirmatrelvir tablets (pink) 150mg*4 tablets + Ritonavir tablets 100mg(white)*2 tablets]*5 blisters/box |
| Conditions Treated | Early mild-to-moderate COVID-19 in adults with severe disease risk factors |
| Taboos | Severe hypersensitivity to either active ingredient; severe hepatic impairment; concurrent use with contraindicated CYP3A4 substrates |
| Place of origin | Nirmatrelvir Tablets: Mooswaldallee 1, Freiburg Im Breisgau, D-79108, Germany/Localita Marino Del Tronto, Ascoli Piceno, I-63100, Italy; Ritonavir Tablets: Unit III, 22-110, Industrial Development Area, Jeedimetla, Hyderabad, Telangana, In-500 055, India |
| Prescription type | Prescription-only |
| Storage Conditions | Sealed packs stored at 15°C–30°C, away from heat and moisture |
| Manufacturer | Nirmatrelvir Tablets: Pfizer Manufacturing Deutschland GmbH/Pfizer Italia SRL; Ritonavir Tablets: Hetero Labs Limited |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | HJ20220006 |
| Approval Date | Feb 11, 2022 |
| Shelf Life | 18 months |
How to use ?
Recommended Dose: Two nirmatrelvir 150mg tablets plus one ritonavir 100mg tablet, twice daily for 5 consecutive days.
Time: All three tablets taken together twice daily within 5 days of symptom onset, with or without food.
Instructions for use: Take all tablets at once per dose; complete the full 5-day course strictly; check all concurrent medicines for CYP3A4 interactions before use.
Interaction: Strong CYP3A4 substrates or inducers cause dangerous concentration fluctuations; many common medicines are contraindicated for combined use.
Side effects: Common: bitter taste, diarrhea, nausea, headache. Rare severe: severe liver function damage, allergic reactions.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What strict time window must be followed to start Nirmatrelvir Tablets and Ritonavir Tablets(co-packaged) this combination antiviral for COVID-19 therapeutic efficacy?
Treatment initiation must happen within five days after the first appearance of COVID-19 symptoms to achieve optimal protective effects against severe progression.
What separate functions do the two components in the combination pack perform during COVID-19 treatment of Nirmatrelvir Tablets and Ritonavir Tablets(co-packaged)?
Nirmatrelvir blocks viral protease to stop virus maturation; ritonavir slows hepatic metabolism to maintain effective blood levels of nirmatrelvir.
What is the full fixed daily dosage and total treatment duration for the standard COVID-19 regimen of Nirmatrelvir Tablets and Ritonavir Tablets(co-packaged)?
Two nirmatrelvir tablets plus one ritonavir tablet taken twice daily for a continuous five-day full course.
What core pre-use assessment is mandatory before prescribing Nirmatrelvir Tablets and Ritonavir Tablets(co-packaged) antiviral to avoid life-threatening risks?
Full review of all concurrent medications is required to rule out dangerous CYP3A4 drug-drug interactions.
PAXLOVID® | Nirmatrelvir Tablets and Ritonavir Tablets (co-packaged) | COVID-19 | DengYueRX
INN: Nirmatrelvir Tablets and Ritonavir Tablets (co-packaged)
Indications: COVID-19
Dosage Form: Tablets
Strength: Nirmatrelvir tablets 150mg/tablet + Ritonavir tablets 100mg/tablet
Original price was: $501.68.$426.43Current price is: $426.43.
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
